Trade

with

Cytori Therapeutics Inc
(NASDAQ: CYTX)
AdChoices
0.5050
-0.0035
-0.69%
After Hours :
0.5050
0.0000
0.00%

Open

0.5230

Previous Close

0.5085

Volume (Avg)

1.43M (569.12k)

Day's Range

0.4900-0.5300

52Wk Range

0.4600-3.93

Market Cap.

40.17M

Dividend Rate ( Yield )

-

Beta

2.44

Shares Outstanding

79.54M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 12.20M

    • Net Income

    • -26.18M

    • Market Cap.

    • 40.17M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -421.90

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.44

    • Forward P/E

    • -5.62

    • Price/Sales

    • 4.08

    • Price/Book Value

    • 33.67

    • Price/Cash flow

    • -1.00

      • EBITDA

      • -21.15M

      • Return on Capital %

      • -96.21

      • Return on Equity %

      • -3,056.03

      • Return on Assets %

      • -96.21

      • Book Value/Share

      • 0.02

      • Shares Outstanding

      • 79.54M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 4.25

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • 0.01

        • Cashflow Estimate

        • -0.22

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -43.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 21.92

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 63.54

            • 82.75

            • Pre-Tax Margin

            • -421.90

            • 39.38

            • Net Profit Margin

            • -421.90

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 67.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -252.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 16.35

              • 0.76

              • Current Ratio

              • 1.23

              • 2.92

              • Quick Ratio

              • 0.88

              • 2.35

              • Interest Coverage

              • -8.24

              • 38.02

              • Leverage Ratio

              • 32.06

              • 2.21

              • Book Value/Share

              • 0.02

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.95

                • 188.68

                • P/E Ratio 5-Year High

                • -18.21

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.88

                • 124.82

                • Price/Sales Ratio

                • 4.01

                • 8.72

                • Price/Book Value

                • 33.11

                • 7.95

                • Price/Cash Flow Ratio

                • -1.00

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -3,056.03

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -96.21

                    (-67.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -121.61

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 0.76

                  • 1.48

                  • Asset Turnover

                  • 0.23

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -30.68M
                  Operating Margin
                  -251.55
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.00
                  Ownership

                  Institutional Ownership

                  33.06%

                  Top 10 Institutions

                  27.57%

                  Mutual Fund Ownership

                  6.92%

                  Float

                  87.47%

                  5% / Insider Ownership

                  2.07%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • iShares Russell 2000 (AU)

                  •  

                    1,074,997

                  • 3.57

                  • 1.02

                  • Vanguard Extended Market Index Fund

                  •  

                    1,061,609

                  • 0.00

                  • 1.33

                  • Vanguard Total Stock Mkt Idx

                  •  

                    919,452

                  • 0.00

                  • 1.16

                  • iShares Russell 2000 Growth

                  •  

                    326,947

                  • 1.34

                  • 0.31

                  • CREF Stock

                  •  

                    234,658

                  • 0.00

                  • 0.30

                  • Bridgeway Ultra Small Company Market

                  •  

                    200,000

                  • 0.00

                  • 0.25

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    195,899

                  • 0.00

                  • 0.25

                  • iShares Micro-Cap

                  •  

                    186,729

                  • 0.00

                  • 0.18

                  • iShares Russell 2000 Value

                  •  

                    146,103

                  • 0.88

                  • 0.14

                  • Vanguard Instl Total Stock Market Index

                  •  

                    139,519

                  • 0.00

                  • 0.18

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • BlackRock Fund Advisors

                  •  

                    2,496,477

                  • +2.61%

                  • 3.14

                  • Vanguard Group, Inc.

                  •  

                    2,345,766

                  • +3.06%

                  • 2.95

                  • Goldman Capital Management Inc

                  •  

                    1,022,288

                  • +171.59%

                  • 1.26

                  • State Street Corp

                  •  

                    898,532

                  • +1.30%

                  • 1.13

                  • Marathon Capital Management LLC

                  •  

                    886,750

                  • +20.98%

                  • 1.11

                  • Perkins Capital Management Inc

                  •  

                    773,329

                  • +29.33%

                  • 0.97

                  • Northern Trust Investments, N.A.

                  •  

                    684,119

                  • -11.52%

                  • 0.86

                  • Princeton Capital Management Inc

                  •  

                    474,805

                  • +6.62%

                  • 0.60

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Core

                  Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celu...moretion System, which extracts the naturally occurring ADRCs from a patient’s own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue bank...moreing lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.lessless

                  Key People

                  Dr. Marc H. Hedrick,M.D.

                  President/Director/CEO

                  David M. Rickey

                  Director/Chairman of the Board

                  Tiago Girao

                  CFO/Vice President, Divisional

                  Steven Kesten

                  Executive VP/Chief Medical Officer

                  Dr. E. Carmack Holmes,M.D.

                  Director

                  • Cytori Therapeutics Inc

                  • 3020 Callan Road

                  • San Diego, CA 92121

                  • USA.Map

                  • Phone: +1 858 458-0900

                  • Fax: +1 858 458-0994

                  • cytori.com

                  Incorporated

                  1997

                  Employees

                  115

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: